To evaluate the pharmacokinetics , safety and survival of trabectedin , metabolized primarily by cytochrome P@ ( CYP ) @A@ enzyme , when coadministered with rifampin ( CYP@A@ inducer ) or ketoconazole ( CYP@A@ inhibitor ) in adult patients with advanced solid tumors .